We have collected information about Sirna Drug Delivery System for you. Follow the links to find out details on Sirna Drug Delivery System.
https://www.sciencedirect.com/science/article/pii/S1818087614000646
4. Potential siRNA drug delivery systems for cancer therapy. Although many strategies that can deliver siRNA into the cytoplasm of cancer cells have been reported, most of them can only satisfy in vitro applications. The majority of siRNA drugs in clinical trials are directly administered to pathology-bearing regions to avoid the complexity of systemic delivery.Author: Cong-fei Xu, Jun Wang
https://www.mdpi.com/journal/pharmaceutics/special_issues/drug_delivery_of_siRNA_therapeutics
A combination of chemotherapeutic drugs and siRNA is emerging as a new modality for cancer therapy. A safe and effective carrier platform is needed for combination drug delivery. Here, a functionalized mixed micelle-based delivery system was developed for targeted co-delivery of methotrexate (MTX) and survivin siRNA.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · Lipid-based siRNA delivery systems include liposomes, micelles, microemulsions, and solid lipid nanoparticles . Liposomes are globular vesicles with an aqueous core and phospholipid bilayer, comprise natural body constituents (e.g., lipids, …Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.sciencedirect.com/science/article/pii/S0169409X19300547
For efficient siRNA delivery, cationic materials that include additional stabilizing interactions (e.g. hydrophobic modifications) and utilize architecture (e.g. well defined polymer morphology, cross-linking) are the most promising. Outside of the classical drug delivery systems, there are also new strategies to develop siRNA therapeutics.Author: Yizhou Dong, Daniel J. Siegwart, Daniel G. Anderson
https://pubs.acs.org/doi/10.1021/bc800278e
Nov 17, 2008 · Small interfering RNA (siRNA) has been chemically conjugated to a variety of bioactive molecules, lipids, polymers, peptides, and inorganic nanostructured materials to enhance their pharmacokinetic behavior, cellular uptake, target specificity, and safety.Author: Ji Hoon Jeong, Hyejung Mok, Yu-Kyoung Oh, Tae Gwan Park
https://www.mdpi.com/1999-4923/12/2/178/pdf
and e ective vectors for siRNA delivery such as liposomes, dendrimers, aptamers, polymer–lipid systems, polymeric, co-polymeric and magnetic nanoparticles. Stiina Kontturi et al., [6] aimed their studies at the development of e cient and safe administration systems devoted to the delivery of oligonucleotide-based drugs. In particular, they produced aAuthor: Gaetano Lamberti, Anna Angela Barba
https://www.ncbi.nlm.nih.gov/pubmed/28423924
However, in vivo systemic siRNA therapy is hampered by the barriers such as poor cellular uptake, instability under physiological conditions, off-target effects and possible immunogenicity. To overcome these challenges, systemic siRNA therapy warrants the development of clinically suitable, safe, and effective drug delivery systems.Author: Aishwarya Singh, Piyush Trivedi, Narendra Kumar Jain
https://www.nature.com/articles/nmat3765
Oct 23, 2013 · Abstract. RNA interference (RNAi) has broad potential as a therapeutic to reversibly silence any gene. To achieve the clinical potential of RNAi, delivery materials are required to transport short interfering RNA (siRNA…Author: Rosemary Kanasty, Joseph Robert Dorkin, Arturo Vegas, Arturo Vegas, Daniel Anderson
http://rnai.technology/rnai-type/top-rani-gene-therapy-companies/
Top RNAi and gene therapy companies, ddRNAi, DNA vaccines
Searching for Sirna Drug Delivery System?
You can just click the links above. The data is collected for you.
